Clinical trial NCT03615313: PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor
Official title: A Clinical Study of PD-1 Antibody Expressing mesoCAR-T Cells for Patients With Mesothelin Positive Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Advanced Solid Tumor
Keywords: mesothelin, PD-1, CAR T cells, solid tumor
Lead sponsor: Shanghai Cell Therapy Research Institute
Sponsor class: OTHER
First posted: 2018-08-03
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to target mesothelin and express PD-1 antibodies in adult patients with advanced recurrent or refractory malignant solid tumors, which were positive expression of mesothelin.

Detailed description: This study will be conducted using a phase I/II trial design to assess the safety and efficacy of the PD-1 antibody expressing mesoCAR-T for patients with mesothelin positive, advanced recurrent or refractory malignant solid tumors. MesoCAR-T can specifically and effectively kill the mesothelin positive cancer cells, PD-1 antibody are secreted from the CAR-T cells could improve immunosuppression microenvironment, new CAR-T cells contain the advantages of CAR-T and immune checkpoint inhibitor, which is a promising therapeutic method for advanced solid tumors.

The new CAR-T therapy is applied to clinical practice as bellow. T cells are prepared from peripheral blood mononuclear cells (PBMC) by leukapheresis, and then activated and engineered to express chimeric antigen receptors (CARs) targeting mesothelin and PD-1 antibody. Cells are proliferated in culture and returned to the patients by venous transfusion therapy. A total of 50 patients may be enrolled in the study. The total duration of the study is expected to be approximately 24 months.

Eligibility criteria: Inclusion Criteria:

1. Patients with relapsed or refractory advanced solid malignancies (diagnosed by histology or cytology detection), including malignant mesothelioma, pancreatic cancer, bile duct cancer, ovarian cancer, lung cancer, gastric cancer, etc.
2. Patients who failed after second-line treatment, or who are unwilling to receive second-line treatment after failed to recieve first-line treatment.
3. Gender unlimited, age from 18 years to 80 years.
4. Life expectancy ≥ 3 months.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
6. Adequate venous access for Peripheral blood mononuclear cell (PBMC) apheresis, and no other contraindications.
7. Immunohistochemistry (IHC) score of mesothelin on tumor tissue ≥ 1+.
8. The requirements of laboratory examination: Neutrophilic granulocyte ≥ 1.0×10\^9/L; Platelet ≥ 50×10\^9/L; Hemoglobin ≥ 90g/L; total bilirubin ≤ 2 times the upper limit of the normal value; Alanine aminotransferase and Aspartate transaminase (ALT and AST) ≤ 2.5 times the upperlimit of the normal value (If there is liver metastasis, they should be ≤ 5 times the upperlimit of the normal value); Serum creatinine ≤ 1.5 times the upper limit of the normalvalue.
9. There is at least one measurable tumor lesion; According to RECIST 1.1 standard, it is suitable to evaluate the therapeutic response and progress of tumor.
10. Patients have adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.
11. Female patients in child bearing period must have evidence of negative pregnancy test or male patients, and they agree to take effective contraceptive measures until 30 days after cells infusion.

Exclusion Criteria:

1. Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment.
2. Patients with seropositive response of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus infection.
3. Patients who are undergoing treatment of autoimmune or organ transplantation diseases, or patients who need long-term use of immunosuppressive drugs such as glucocorticoid.
4. Patients with severe heart and lung dysfunction, high blood pressure and cannot be controlled with medicine, unstable coronary artery disease (uncontrolled arrhythmias, unstable angina pectoris), uncompensated congestive heart failure, myocardial infarction within six months.
5. Patients with any other illness that the investigators consider it will may affect the patient's treatments, follow-up or assessment, including any uncontrolled clinically significant neurological or psychiatric disorders, immunoregulatory diseases, metabolic diseases, infectious diseases and so on.
6. Received cancer treatment prior to enroll the group within the following time (including drug clinical trials):

(1) The withdrawal time of chemotherapy before enrollment was shorter than the treatment cycle of chemotherapy.

(2) The use of anti-tumor therapy within 4 weeks before the study or less than 5 times of the half-life period of the drugs (including radiation therapy, chemotherapy, small molecules and biological therapy or immunotherapy), the shortest period of time was as the criterion (but the shortest time should not be less than 21 days).

7. Women patients in pregnancy period or suckling period.

Primary outcomes:
measure: Incidence of treatment-related adverse events of infusion of autologous PD-1 antibody expressing mesothelin-targeted CAR-Tcells
timeFrame: 2 years
Secondary outcomes:
measure: Objective response rate (ORR) of the treatment using PD-1 antibody expressing mesoCAR-T cells for advanced solid tumors
timeFrame: 2 years
measure: Progression free survival
timeFrame: 2 years
measure: Overall survival
timeFrame: 2 years
Other outcomes:
measure: Proliferation and persistence of mesothelin specific CAR-T cells in peripheral blood of the patients
timeFrame: 6 months
measure: PD-1 antibody level in peripheral blood of the patients after treatment
timeFrame: 6 months
Locations:
city: Shanghai
country: China
facility: China
state: Shanghai
Study officials:
affiliation: Shanghai Cell Therapy Research Institute
name: Qijun Qian, PhD
role: STUDY_CHAIR
affiliation: Shanghai Cell Therapy Research Institute
name: Huajun Jin, PhD
role: STUDY_CHAIR
affiliation: Shanghai 10th People's Hospital
name: Qing Xu, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Shanghai Cell Therapy Research Institute
name: Zhiwei Zhang, PhD
role: STUDY_DIRECTOR
affiliation: Shanghai Cell Therapy Research Institute
name: Yan Sun
role: STUDY_DIRECTOR
affiliation: Shanghai Cell Therapy Research Institute
name: Huimei Li, PhD
role: STUDY_DIRECTOR
affiliation: Shanghai 10th People's Hospital
name: Juemin Fang, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Shanghai 10th People's Hospital
name: Song Gao, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Shanghai 10th People's Hospital
name: Xianling Guo
role: PRINCIPAL_INVESTIGATOR
affiliation: Shanghai 10th People's Hospital
name: Hui Wang
role: PRINCIPAL_INVESTIGATOR
affiliation: Shanghai 10th People's Hospital
name: Zhongzheng Zhu
role: PRINCIPAL_INVESTIGATOR
affiliation: Shanghai 10th People's Hospital
name: Jianhua Chen
role: PRINCIPAL_INVESTIGATOR
References:
citation: Fang J, Ding N, Guo X, Sun Y, Zhang Z, Xie B, Li Z, Wang H, Mao W, Lin Z, Qin F, Yuan M, Chu W, Qin H, Qian Q, Xu Q. alphaPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib. J Immunother Cancer. 2021 Feb;9(2):e001162. doi: 10.1136/jitc-2020-001162.